Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 11, 2015 - Issue
Submit an article Journal homepage
65
Views
8
CrossRef citations to date
0
Altmetric
Review

Emerging therapeutic options for sporadic inclusion body myositis

Lindsay N AlfanoNationwide Children’s Hospital, Center for Gene Therapy, Columbus, OH, USACorrespondence[email protected]
&
Linda P LowesNationwide Children’s Hospital, Center for Gene Therapy, Columbus, OH, USA
Pages 1459-1467 | Published online: 25 Sep 2015

Figures & data

Figure 1 Progress of drug development and testing in IBM on a scale from not currently supported or recommended based on best available evidence to full approval.

Abbreviations: TNF, tumor necrosis factor; IBM, inclusion body myositis; X, not supported by current evidence, no current studies underway.
Figure 1 Progress of drug development and testing in IBM on a scale from not currently supported or recommended based on best available evidence to full approval.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.